Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Not yet accepting
CARTITUDE-2
Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- Phase 2
Accepting patients
MonumenTAL-3
Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 3
Not yet accepting
MonumenTAL-8
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Learn more- Bispecific Antibody
- CAR T Cell
- BCMA
- GPRC5D
- Phase 2
Accepting patients
CAMMA-2
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)
Learn more- Bispecific Antibody
- FCRH5
- Phase 1/2
Accepting patients
ADVANCE
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)
Learn more- Monoclonal Antibody
- CD38
- Phase 2
Not yet accepting
UltraFrailMM
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma: A Phase 2 Multicenter Study
Learn more- Monoclonal Antibody
- CD38
- Phase 2
Accepting patients
CaMMouflage
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn more- CAR T Cell (Allogeneic)
- BCMA
- Phase 1
Accepting patients
DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Phase 3
Accepting patients
BGB-11417
A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Learn more- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
ABBV-383
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- Gamma-Secretase Inhibitor
- BCMA
- Phase 1
4 hidden based on your filters. Show All